Targeted Therapeutics Research Award
Funded equally by LUNGevity Foundation and the American Lung Association National Office
Nouri Neamati, PhD
University of Southern California
Los Angeles
CA
Dr. Neamati is carrying out in-depth preclinical studies on a prototype compound, SC21. He is studying where the SC21 compound travels in the body, its safety, and its effectiveness in non-small cell lung cancer (NSCLC), with the ultimate goal of bringing SC21 to the clinic.